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Abstract Excessive consumption of highly palatable
food has been linked to the development of eating disorders
and obesity, and can be modeled in non-food-deprived rats
by offering them a limited (2-h daily) access to an optional
dietary fat. Since the glutamatergic system has recently
emerged as a viable target for binge-eating medication
development, we compared the effects of subchronic
treatment with glutamatergic receptor antagonists to the
effects of a reference appetite-suppressing agent sibutr-
amine on highly palatable food (lard) and normal chow
intake. In three separate experiments, the consumption of a
standard laboratory chow and lard were measured during
12 days of medication treatment and for 6 days afterwards.
Generalized estimating equations analysis demonstrated
that sibutramine (7.5 mg/kg, PO) significantly decreased
lard consumption, with a concurrent increase in chow
consumption. Sibutramine effects disappeared after treat-
ment discontinuation. The NMDA receptor antagonist
memantine (5 mg/kg, IP) significantly decreased lard
consumption and increased chow consumption, compara-
ble to effects of sibutramine; however, memantine’s effects
persisted after treatment discontinuation. The effects of the
mGluR5 antagonist MTEP (7.5 mg/kg, IP) on food con-
sumption were in the same direction as seen with
memantine, but the observed differences were not signifi-
cant. In an additional control experiment, sibutramine and
memantine reduced unlimited (24 h) chow intake during
the treatment phase. Present results provide evidence that
glutamatergic neurotransmission might be involved in the
regulation of excessive consumption of highly palatable
foods, and suggest that NMDA receptor may be an
attractive target for developing obesity and disordered
eating pharmacotherapies.
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Introduction
Excessive, non-homeostatic consumption of highly palat-
able food has been linked to eating disorders and obesity
(Berthoud 2004; Blundell and Finlayson 2004; Boggiano
et al. 2009; Hagan et al. 2003; Vartanian et al. 2007; Walsh
and Devlin 1998). Exposure to highly palatable food dis-
rupts natural mechanisms of appetite regulation and results
in abnormal patterns of consumption such as binge-eating
and compulsive overeating (Devlin et al. 2000; Erlanson-
Albertsson 2005; Fairburn et al. 2000; Tanofsky-Kraff
et al. 2006).
Development of animal models of binge-type con-
sumption of highly palatable food can hasten study of
underlying mechanisms and discovery of pharmacothera-
pies (Avena et al. 2009; Bisaga et al. 2008; Cifani et al.
2009; Corwin and Buda-Levin 2004; Foltin et al. 2008;
Wojnicki et al. 2008a). In one such model, non-food-
deprived laboratory rats with unlimited access to chow are
offered a limited access to an optional source of dietary fat.
After several weeks of limited access to fat and a contin-
uous access to chow, the rats develop eating pattern char-
acterized by consumption of large amounts of the fat
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during brief access periods (2 h per day) and this effect is
enhanced when the fat is offered only three times per week
(Buda-Levin et al. 2005; Corwin and Buda-Levin 2004;
Corwin et al. 1998; Wojnicki et al. 2008a, b; Wong et al.
2009). It has been proposed that this behavioral paradigm
can be used as a model of binge-eating, as it mimics fea-
tures of clinical syndrome such as rapid consumption of
highly palatable food (Devlin et al. 2003; Weltzin et al.
1991). However, its predictive validity to detect effects of
anti-binge medications is less known (Buda-Levin et al.
2005). The first goal of the present study was thus to assess
the utility of the limited access model as a screening tool in
binge-eating pharmacotherapy development using sibutr-
amine, a prototypic weight loss medication that has been
found to reduce binge-eating in patients with binge-eating
disorder (Wilfley et al. 2008). In order to assess the
selectivity of medication effect on the consumption of lard
in the situation of choice, we have conducted a separate
experiment evaluating the effect of sibutramine on the
consumption of chow, available 24 h per day.
The glutamatergic neurotransmitter system is a viable
target for binge-eating disorder medication development in
view of its role in the reinforced and consummatory
behaviors produced by drugs of abuse and highly palatable
food (Bisaga and Popik 2000; Bradbury et al. 2005; Gass
and Olive 2008; Herman et al. 2003; Popik et al. 2003). We
have previously shown in baboons, that single doses of
memantine and MTEP produce decrease in the consump-
tion of highly palatable food (candy) comparable to effects
of dexfenfluramine, another prototypic binge-eating
reducing medication (Bisaga et al. 2008; Foltin et al. 2008).
The second goal of the present study was therefore to
evaluate the effects of the NMDA receptor antagonist
memantine and the mGluR5 antagonist MTEP and to
compare those effects to the effects of sibutramine in the
limited-access animal model of binge-eating of highly
palatable food (lard) and on the consumption of chow
available at all times. We were interested in evaluating
effects of repeated drug treatment as well as drug carry-
over effects, because longer-term dosing is more relevant
to the clinical medication development. We hypothesized,
that memantine and MTEP would have an effect compa-
rable to the effect of sibutramine.
Materials and methods
Subjects
All experimental procedures were conducted in accordance
with the NIH Guide for the care and use of laboratory
animals and were approved by the Ethics Committee for
animal experiments, Institute of Pharmacology. Male
Sprague-Dawley rats (Prokocim, Krako´w, Poland) weigh-
ing *300 g were housed individually at 21 ± 2C (A/C
controlled) on the 12-h light/dark cycle (lights on 06:00).
Procedure
The present work consisted of two sets of experiments. In
experiments 1–3, we separately tested the effects of med-
ications in the limited access to the lard model and in
experiment 4, we tested the effects of medications and
vehicle on the unlimited chow consumption.
Experiments 1–3
A modified limited access procedure (Corwin et al. 1998)
was used to induce binge-type consumption of lard.
Throughout the 6 weeks of the study, rats had an unlimited
access to the standard laboratory chow (Labofeed H,
Kcynia, Poland, containing 3.12 kcal/1 g: 22% protein,
4% fat, 11.5% fibers and ashes) and tap water. In addition,
a feeder with lard (JAGR, Warlubie, Poland, 9.0 kcal/1 g:
100% fat) was introduced daily for 2 h, starting 2 h prior to
lights out (Lard Session). After 3 weeks of individual
housing, a consumption of lard and chow had stabilized
(data not shown) and the drug administration was initiated.
In view of the fact that sibutramine, memantine and MTEP
had a different route of administration and different vehi-
cles, three separate experiments were conducted consecu-
tively. In each, two groups of rats were matched by the
amount of lard consumed during the pre-treatment phase
and assigned to receive the study drug or its vehicle.
A disadvantage of such experimental design was that the
experiments were carried out at different seasons of the
year, using animals that differed in the baseline body
weight and amount of food consumed. The drugs were
given once daily for 12 consecutive days (Treatment
Phase), immediately prior to the Lard Session, i.e., at
1600 hours. Following Treatment Phase, animals were
given vehicle daily for 6 days while other study procedures
were identical and food consumption was monitored, to
investigate possible carryover effects (Post-Treatment
Phase). Nine animals were assigned to each sibutramine
and its vehicle groups (Exp. 1), 10 animals assigned to each
memantine and its vehicle groups (Exp. 2), and 8 animals
assigned to each MTEP and its vehicle groups (Exp. 3).
Experiment 4
In a separate control experiment, a group of different rats
was acclimated to cages with an unlimited access to the
standard laboratory chow and tap water (continuous access
to chow procedure). After the initial phase of individual
housing lasting for 2 weeks, the consumption of chow
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stabilized (data not shown) and rats were separated into
four groups. Each group was assigned to receive one of the
three study drugs or the vehicle. The drugs were given at
1600 hours once daily for 7 consecutive days (Treatment
Phase), after the assessment of previous day’s chow con-
sumption. Following Treatment Phase, animals were given
vehicle, but other study procedures were identical and food
consumption was monitored daily for 5 days of Post-
Treatment Phase. Twelve animals were assigned into each
of the study drugs and 13 animals were assigned into the
pooled vehicle group (5 received saline IP, 4 received
Tween IP, and 4 received Tween PO).
Drugs
MTEP HCl (3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyri-
dine, MERZ Pharmaceuticals) and sibutramine HCl
(Abbott; purchased as a commercial formulation) were
suspended right before administration in 1% Tween 80/
distilled water solution with pH adjusted 6–6.5 with NaOH.
Memantine HCl (MERZ Pharmaceuticals) was dissolved in
sterile physiological saline. MTEP (7.5 mg/kg) and
memantine (5 mg/kg) and their respective vehicles were given
IP, while sibutramine (7.5 mg/kg) and its vehicle were
administered PO. The doses of sibutramine, memantine and
MTEP were chosen based on earlier observations showing
inhibitory effects of these compounds on either food intake
or reinforcing effects of abused drugs (Bradbury et al. 2005;
Jackson et al. 1997; Popik et al. 2003, 2006).
Statistical analyses
In the limited access experiments (Experiments 1–3; with
sibutramine, memantine, and MTEP, respectively), the
amounts of lab chow and the lard consumed during the 2-h
Lard Session were measured daily and recalculated as
energy (Kcal) per body weight in grams. Food consumption
was measured for 12 consecutive days during drug treat-
ment (Treatment Phase) and for 6 consecutive days after-
wards (Post-Treatment Phase). In Experiments 1–3, we
evaluated the effect of Drug (active or vehicle), Food type
(lard or chow), phase (Treatment or Post-Treatment), and
Time (day as a continuous variable) on food consumption.
In the continuous access experiment (Experiment 4), the
amount of lab chow consumed during 24 h was measured
daily and recalculated as energy (Kcal) per body weight in
grams. Food consumption was measured at pre-treatment
baseline, for 7 consecutive days during drug treatment
(Treatment Phase) and for 5 consecutive days afterwards
(Post-Treatment Phase). In this experiment, we evaluated
the effects of drug (sibutramine, memantine, or MTEP),
phase (Treatment or Post Treatment) and time (days as a
continuous variable).
The choice of this statistical method deserves a brief
note. Traditional test statistics such as the v2 or t test could
not be used to test for food and drug-related differences in
Experiments 1–3 due to the lack of independence across
measurements (i.e., consumption of one food being corre-
lated with consumption of another food) and our interest in
consumption changes over time. To address this issue, we
used generalized estimating equations (GEE) statistical
approach involving estimation of marginal models to fit
consumption as a function of drug, food type, phase, and
time as well as all their interactions. A backward elimi-
nation procedure starting with the four-way interaction was
used to select the best-fit, final model. The GEE approach
for repeated measurements was used to estimate and test
the model. This procedure is best suited to analyze corre-
lated data obtained in longitudinal studies, which allows to
test the effect of intervention at various time-points during
treatment and at follow-up (Lee et al. 2007; Zeger and
Liang 1986). The GEE methodology requires no para-
metric distribution assumption, provides robust inference
with respect to misspecification of the within subject cor-
relation and allows for the analysis of continuous, cate-
gorical and count data. PROC GENMOD in SAS 9.1 was
used to carry out analyses. A one-way ANOVA with
Tukey’s HSD post hoc test was used to conduct additional
analyses in experiment 4.
Changes in body weight of the rats used in experiments
1–4 were assessed independently for each experiment with
the use of two-way repeated measures ANOVAs with the
week as the repeated factor and treatment as the between-
subjects factor.
Results
Experiment 1
For sibutramine dataset, a parsimonious model for lard and
chow consumption was used (Table 1; Fig. 1a). Through-
out the observation period, animals consumed more lard
than chow (v2 = 5.87, p = 0.015).
Sibutramine decreased overall food consumption
(p = 0.028); however, this effect was different for lard and
chow (significant Drug 9 Food interaction p = 0.049).
While sibutramine decreased the consumption of lard, it
increased the consumption of chow. The effect of sibutr-
amine on lard and chow consumption disappeared during
the Post-Treatment Phase.
Experiment 2
For memantine dataset, the separate models for lard and
chow consumption were fitted since the parsimonious
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model could not provide reasonable fit for both food types
simultaneously (Table 2; Fig. 1b).
For Lard, memantine decreased overall consumption
(p = 0.028). There was a marginal effect of Phase
(p = 0.052) and a significant Time x Phase interaction
(p = 0.03), indicating that lard consumption increased over
time in the Treatment Phase while it decreased in Post-
Treatment Phase.
For Chow, memantine increased overall consumption
(p = 0.003), with the drug effect appeared significantly
greater for Treatment than for the Post-Treatment Phase
(significant Drug 9 Phase interaction p = 0.05).
Experiment 3
For MTEP dataset, separate models for lard and chow
consumption were used for the same reason as in me-
mantine dataset (Table 3; Fig. 1c).
Animals treated with MTEP consumed less lard, but this
effect was not significant (p = 0.196). There was no sig-
nificant difference between two Treatment groups and
different Treatment Phases and there was no significant
Time trend.
For the chow, MTEP appeared to increase consumption
during Treatment Phase, however, the drug effect
disappeared after treatment was stopped (significant
Drug 9 Phase interaction p = 0.004) rendering overall
drug effect statistically not-significant (p = 0.075).
Experiment 4
In the GEE model that was fitted for this dataset, the effects
of each study drug was compared to the effects of pooled
vehicle. Overall food consumption was significantly dif-
ferent among the four treatment groups (p = 0.008), with
animals on sibutramine consuming the least food during
the experiment (Fig. 2). On average, food consumption
was lower during the treatment phase of the experiment
(p \ 0.0001), and changed over time (p = 0.001). None-
theless, as illustrated in Table 4 and Fig. 2, there was
a significant three-way interaction between Treatment,
Time and Phase of the treatment (p = 0.02).
In order to determine whether food consumption was
significantly lower in animals treated with each of study
drugs as compared to animals treated with vehicle during
the treatment phase we conducted one-way ANOVA
comparing areas under the curve for food consumption
(Fig. 2, days 11–18). This analysis showed a significant
effect of the drug: F3,45 = 4.12, p \ 0.05, with rats
treated with sibutramine or memantine consuming sig-
nificantly less food than rats treated with vehicle
(p = 0.019; p = 0.024, respectively, Tukey’s HSD test).
As seen on the Fig. 2, effect of sibutramine changed
over time and was most evident at the beginning of
treatment while the effect of memantine was evident
throughout treatment phase.
Changes in body weight (Experiments 1–4)
As shown of Fig. 3, all the groups have shown a gradual
gain of the body weight over the time of experiments. Two-
way repeated measures ANOVAs with treatment as
between-subjects factor, week as repeated factor and
interaction revealed the following values: F1,96 = 1.549,
NS; F6,96 = 314.9, p \ 0.001; F6,96 = 2.996, p \ 0.01 for
sibutramine experiment; F1,108 = 0.01, NS; F6,108 =
392.2, p \ 0.001; F6,108 = 0.25, NS for memantine
experiment, and F1,84 = 1.0, NS; F6,84 = 165, p \ 0.001
and F6,84 = 1.0, NS for MTEP experiment, respectively.
Despite significant interaction in sibutramine experiment,
there was no significant difference between groups at any
time-point as revealed by the post hoc Bonferroni’s test.
Animals used in Experiment 4 were never offered the
lard, and 2-way repeated measures ANOVA with treatment
as between-subjects factor, week as repeated factor and
interaction revealed the significant effect of week
(F3,135 = 458.9, p \ 0.001) but no effect of treatment
(F3,135 = 0.22, NS) or interaction (F9,135 = 1.09, NS).
Table 1 Sibutramine experiment GEE score statistics with food
consumption as outcome variable
Source BSE v(1)
2 p Value
Intercept 317.4 (90.0)
Fooda -291.1 (96.7) 5.87 0.0154
Drugb -297.5 (103.4) 4.84 0.0278
Drug 9 food 319.6 (117.4) 3.87 0.0491
Time -6.17 (2.23) 2.20 0.1382
Time 9 food 5.68 (2.42) 0.46 0.4966
Time 9 drug 7.48 (2.61) 4.17 0.0412
Time 9 drug 9 food -8.06 (3.00) 2.85 0.0916
Phasec -244.9 (86.6) 4.81 0.0282
Phase 9 food 223.6 (89.7) 1.03 0.3102
Drug 9 phase 296.7 (101.9) 4.60 0.0319
Drug 9 phase 9 food -331.3 (110.8) 5.97 0.0146
Time 9 phase 7.21 (2.48) 5.04 0.0248
Time 9 phase 9 food -6.74 (2.50) 1.54 0.2147
Time 9 drug 9 phase -8.25 (2.97) 3.99 0.0459
Time 9 drug 9 phase 9 food 9.40 (3.14) 5.97 0.0146
Effects in table are food type (lard or chow), drug (sibutramine or
vehicle), phase (Treatment or Post-Treatment), and time-receiving
treatment is in units of days (22–33) for consumption outcome (kcal/
kg b.w.). Bold p values denote significant effects
a Lard was used as the reference
b Vehicle was used as the reference
c Post-treatment phase was used as the reference
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Discussion
Providing rats with an opportunity to consume a highly
palatable food (lard) and a standard chow diet yielded a rapid
and robust, ‘‘binge-like’’ level of lard consumption. Animals
acquired significantly more energy from lard, which was
available only for 2 h daily, than from chow, which was
available at all times. Animals consumed large amounts lard
despite their sated condition. This paradigm models a clin-
ical phenomenon of an excessive, binge-type food con-
sumption, where individuals repeatedly seek out and
consume large amounts of highly palatable food, in a brief
and discrete period of time (Weltzin et al. 1991). The
validity of this model to detect clinically effective medica-
tions was confirmed using sibutramine. The effects of
chronic treatment with sibutramine to decrease energy
intake in the proposed model are consistent with its effects to
decrease food intake and binge-eating in the clinical setting
(Arterburn et al. 2004; James et al. 2000; Wilfley et al. 2008)
and in the human laboratory (Mitchell et al. 2003). The
model of binge-eating of highly palatable food used here
does not fully reflect other clinical features of human binge-
eating such as binge-eating despite negative consequences
or an increase of binge-eating in response to stress.
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Fig. 1 2-h consumption of lard and chow at baseline, during repeated
treatment with sibutramine (a), memantine (b) or MTEP (c), and
during post-treatment phase. The group means, the GEE-fitted lines,
and the p value for between-group differences (medication vs. vehicle
control) are shown. Number of animals in each group N = 9 a,
N = 10 b, N = 8 c
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However, this model can be used to study effects of medi-
cations on the consumption of highly palatable fatty foods.
Chronic treatment with sibutramine produced an overall
decrease in energy intake, primarily due to decreased lard
consumption. Interestingly, at the same time as animals
decreased consumption of lard, they increased consump-
tion of chow. This suggests a selective reduction of highly
palatable food consumption with a compensatory increase
of chow consumption rather than a global suppression of
eating. After sibutramine treatment was stopped, the effect
of treatment disappeared, as both groups consumed the
baseline amount of energy from lard and chow by the end
of the Post-Treatment Phase. This confirms that the
observed effect was pharmacologically specific but rela-
tively short-lasting. Memantine produced an effect on lard
consumption that was similar to that of sibutramine, but
unlike with sibutramine, the medication effect persisted
throughout the Post Treatment Phase. Similarly to sibutr-
amine, a compensatory increase in chow consumption
under memantine occurred only during the Treatment
Phase. MTEP produced a small decrease in lard con-
sumption, and a compensatory increase in chow con-
sumption during the medication Treatment phase, but these
changes were not statistically different from that of the
vehicle-treated group. Overall the effects of MTEP on lard
and chow consumption were in the predicted direction, and
similar to effects of sibutramine and memantine. In a
control experiment, effects of study drugs were assessed in
animals that were offered only the chow, though with an
unlimited access. Under these conditions, repeated treat-
ment with sibutramine produced initially a significant
decrease in chow consumption, but this effect disappeared
quickly. Treatment with memantine also produced decrease
of chow consumption but only during the treatment phase,
while treatment with MTEP had no effect on unlimited
chow consumption.
When animals were given a choice to consume chow or
lard, but access to lard was limited to only 2 h per day, they
consumed a large amount of lard. Results observed here are
consistent with other studies showing that limited access to
highly palatable food produces a ‘‘binge-type’’ pattern of
consumption in rats (Corwin et al. 1998; Wojnicki et al.
2008b; Wong et al. 2009) and baboons (Bisaga et al. 2008).
The memantine-induced decrease in binge-type consump-
tion of highly palatable food confirms earlier positive
findings of memantine’s effects in animal models of binge-
eating disorder (Bisaga et al. 2008; Foltin et al. 2008). In
laboratory animals, the pattern of binge-consumption of
highly palatable foods is comparable to the binge pattern of
drug and alcohol consumption (Colantuoni et al. 2001;
Corwin et al. 1998). Considering that both NMDA recep-
tors (Bisaga and Popik 2000; Herman et al. 2003) as well as
mGlu5 receptors (Chiamulera et al. 2001) are involved in
various manifestations of drug dependence and addiction,
we hypothesize that binge-eating and binge pattern of drug
and alcohol consumption may have shared regulatory
mechanisms. Therefore, treatments developed for drug and
alcohol addictions might be effective for the treatment of
binge-eating. In the present study, treatment with MTEP
did not produce clear effects on food intake, unlike what
was previously shown in a baboon model (Bisaga et al.
2008). The fact that the effects of MTEP were in a similar
Table 2 Memantine experiment GEE score statistics with food
consumption as outcome variable for separate Lard and Chow models
Source BSE v(1)
2 p Value
LARD
Intercept 150.7 (67.0)
Druga 28.9 (11.6) 4.80 0.0284
Time -2.56 (1.78) 0.07 0.7984
Phaseb -142.7 (66.0) 3.78 0.0519
Time 9 phase 4.64 (1.88) 4.67 0.0307
CHOW
Intercept 5.16 (6.20)
Druga -5.75 (2.00) 9.00 0.0027
Phaseb 6.53 (2.10) 5.70 0.0170
Drug 9 phase -3.24 (1.47) 3.85 0.0498
Time 0.15 (0.18) 0.64 0.4245
Effects in table are drug (memantine or vehicle), phase (Treatment or
Post-Treatment), and time-receiving treatment is in units of days (21–
32) for consumption outcome (kcal/kg b.w.). Bold p values denote
significant effects
a Memantine was used as the reference
b Post-treatment phase was used as the reference
Table 3 MTEP experiment GEE score statistics with food con-
sumption as outcome variable for separate Lard and Chow models
Source BSE v(1)
2 p Value
LARD
Intercept 2.74 (5.31)
Druga -0.62 (1.52) 1.67 0.1959
Phaseb 7.27 (1.84) 0.00 0.9738
Time 0.28 (0.15) 1.72 0.1903
CHOW
Intercept 1.35 (6.22)
Time 0.31 (0.17) 2.74 0.0980
Druga -0.91 (2.18) 3.17 0.0750
Phaseb 7.84 (1.82) 6.41 0.0114
Drug 9 phase -6.10 (1.44) 8.43 0.0037
Effects in table are drug (MTEP or vehicle), phase (Treatment or
Post-Treatment), and time-receiving treatment is in units of days (21–
32) for consumption outcome (kcal/kg b.w.). Bold p values denote
significant effects
a MTEP was used as the reference
b Post-treatment phase was used as the reference
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direction to the effects of memantine albeit much weaker,
may suggest that the dose of MTEP used was inadequate.
In the present experiments, we used a 7.5 mg/kg dose of
MTEP as compared to a 5 mg/kg dose of memantine. In
baboons, doses of MTEP that produce comparable
decreases in candy consumption were approximately twice
as large as respective doses of memantine. On the other
hand, a recent study demonstrated that MTEP and
memantine produce effects on the behavior of rats in the
social interaction test in a similar range of doses (Koros
et al. 2007). Alternatively, it cannot be excluded that the
experiment conducted at a different season of the year
resulted in an overall decrease of food intake resulting in an
insignificant effect of the medication. This is certainly the
limitation of the design used in the present study.
In the present study, the effects of memantine, an
uncompetitive NMDA receptor antagonist, were compa-
rable to the effects of sibutramine, a serotonin and nor-
adrenaline reuptake inhibitor. This similarity in findings
confirms that glutamatergic mechanisms may be as
important as serotonergic mechanisms in regulating food
consumption (Rammes et al. 2008). More interestingly,
while the inhibitory effects of sibutramine on lard-bingeing
were restricted to the treatment phase, a memantine-
induced decrease appeared to persist even after the treat-
ment was discontinued. Memantine is known to block the
expression of neuroadaptations associated with the
rewarding effects of potent reinforcers (Bisaga and Popik
2000) and was shown to inhibit relapse to opiate seeking
even long after treatment discontinuation (Popik et al.
2006). We hypothesize that memantine prevented rebound
relapse to binge-type fat consumption via a similar neu-
roadaptive mechanism.
We showed that under the condition of concurrent access
to standard as well as highly preferred food both sibutramine
and memantine selectively decreased consumption of lard
but not chow. However, when only standard food was
available, both sibutramine and memantine reduced food
consumption, though animals rapidly developed tolerance to
the consumption-suppressing effects of sibutramine. This
suggests that in a situation of choice, these agents selectively
alter the reinforcing effects of food with a higher palatability
and reinforcing efficacy. This is consistent with the selective
effects of memantine to reduce consumption of highly pal-
atable food observed in the baboon model of binge-eating
(Foltin et al. 2008). Therefore, in the situation of concurrent
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Fig. 2 24-h consumption of unlimited access chow at baseline,
during repeated treatment with sibutramine, memantine, or MTEP
and during post-treatment phase. Figure shows the group
means ± SEM and the GEE-fitted lines: solid, dotted, dash-dotted
and dashed for vehicle, sibutramine, memantine and MTEP, respec-
tively. Number of animals in each group was 12–13
Table 4 Experiment 4 GEE score statistics with food consumption
(kcal/kg b.w.) as outcome variable in four groups of animals with
unlimited access to chow
Source BSE v2 df p Value
Intercept 316.2 (23.0)
Druga
Memantine 29.9 (40.7) 11.7 3 0.008
Mtep 19.3 (41.6)
Sibu -13.1 (27.3)
Phaseb -31.7 (28.7) 23.9 1 \0.0001
Time -4.48 (1.04) 10.4 1 0.001
Drug 9 phase
Memantine -76.5 (49.8) 10.5 3 0.015
Mtep -54.9 (36.4)
Sibu -229.1 (53.5)
Drug 9 time
Memantine -1.24 (1.82) 12.0 3 0.008
Mtep -1.14 (1.90)
Sibu 1.44 (1.22)
Time 9 period 0.57 (1.61) 18.2 1 \0.0001
Drug 9 phase 9 time
Memantine 3.10 (2.71) 10.0 3 0.018
Mtep 2.83 (1.88)
Sibu 12.9 (3.05)
Effects in table are drug (sibutramine, memantine, MTEP or vehicle),
phase (Treatment or Post-Treatment), and time (days)
a Vehicle was used as the reference
b Post-treatment phase was used as the reference
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access to different types of food memantine appears to be
selective in reducing the reinforcing effects of food that is
likely to be consumed for its hedonic rather than its
homeostatic properties (Saper et al. 2002). This effect is
comparable to the effect of memantine in selectively
decreasing the effects of strongly rewarding stimuli, such as
sexual interaction and morphine, but not of regular food
(Popik et al. 2003). However, memantine can also produce
decrease in the standard food consumption, presumably by
enhancing satiation as seen previously (Bisaga et al. 2008;
Foltin et al. 2008).
The ‘‘ideal’’ anti-binge medications should reduce non-
homeostatic food intake while leaving normal food intake
unaffected; and the normalizing effect of medication on
eating behavior should persist beyond the period of drug
treatment (Yanovski 2003). Results of the present study, as
well as previous studies using animal models (Bisaga et al.
2008; Foltin et al. 2008), suggest that memantine may have
a uniquely attractive profile of clinical effectiveness. Initial
uncontrolled clinical observations confirm the safety and
potential effectiveness of memantine in reducing binge-
eating with less effect on weight (Brennan et al. 2008;
Hermanussen and Tresguerres 2005). Moreover, weight
loss was not seen in memantine-treated patients with
dementia (McShane et al. 2006) suggesting that memantine
may possess a favorable clinical profile of effectiveness in
reducing abnormal eating.
In summary, the present study provides evidence that
chronically administered memantine, an NMDA receptor
glutamatergic antagonist, can selectively decrease con-
sumption of highly palatable food with less effect on the
consumption of a standard diet, and that this effect persists
after the medication is discontinued. These findings suggest
that memantine and NMDA receptor neurotransmission
may be an attractive target for developing effective phar-
macotherapies for binge-eating disorder and obesity.
Acknowledgments The assistance of Dr. Wojciech Danysz in
obtaining funding for this study, Ms. Wendy Cheng for providing
statistical consultation, and the assistance of Mr. Sean Ortman in
editing the manuscript is gratefully acknowledged. Writing of this
study was supported by the Funds for Statutory Activity of the
Institute of Pharmacology Polish Academy of Sciences.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
Arterburn DE, Crane PK, Veenstra DL (2004) The efficacy and safety
of sibutramine for weight loss: a systematic review. Arch Intern
Med 164:994–1003
Avena NM, Rada P, Hoebel BG (2009) Sugar and fat bingeing have
notable differences in addictive-like behavior. J Nutr 139:623–628
Experiment 1: sibutramine
0 1 2 3 4 5 6 7
250
300
350
400
vehicle
sibutramine
Weeks of experiment
Bo
dy
 w
ei
gh
t [g
]
Experiment 2: memantine
0 1 2 3 4 5 6 7
225
275
325
375
vehicle
memantine
Weeks of experiment
Bo
dy
 w
ei
gh
t [g
]
Experiment 3: MTEP
0 1 2 3 4 5 6 7
325
375
425
475
vehicle
MTEP
pre-treatment treatment post-treatment
Weeks of experiment
Bo
dy
 w
ei
gh
t [g
]
Experiment 4: 24 hour unlimited access to the chow
0 1 2 3 4
250
275
300
325
350
vehicle
sibutramine
memantine
MTEP
Weeks of experiment
Bo
dy
 w
ei
gh
t [g
]
pre-treatment treatment post-treatment
pre-treatment treatment post-treatmentpre-treatment treatment post-treatment
Fig. 3 Body weight of all the groups tested. Panels show group
means ± SEM. Panels 1–3 represents rats that were offered a limited
access to the lard since the beginning of the experiment and were
treated with respective medications during the treatment phase. Panel
4 represents rats that had continuous access to chow but no access to
lard
484 P. Popik et al.
123
Berthoud HR (2004) Neural control of appetite: cross-talk between
homeostatic and non-homeostatic systems. Appetite 43:315–317
Bisaga A, Popik P (2000) In search of a new pharmacological
treatment of drug addiction: N-methyl-D-aspartate (NMDA)
antagonists. Drug Alcohol Depend 59:1–15
Bisaga A, Danysz W, Foltin RW (2008) Antagonism of glutamatergic
NMDA and mGluR5 receptors decreases consumption of food in
baboon model of binge-eating disorder. Eur Neuropsychophar-
macol 18:794–802
Blundell JE, Finlayson G (2004) Is susceptibility to weight gain
characterized by homeostatic or hedonic risk factors for over-
consumption? Physiol Behav 82:21–25
Boggiano MM, Dorsey JR, Thomas JM, Murdaugh DL (2009) The
Pavlovian power of palatable food: lessons for weight-loss
adherence from a new rodent model of cue-induced overeating.
Int J Obes (Lond) 33:693–701
Bradbury MJ, Campbell U, Giracello D, Chapman D, King CD,
Tehrani L, Cosford ND, Anderson J, Varney MA, Strack AM
(2005) Metabotropic glutamate receptor, mGlu5, is a mediator of
appetite and energy balance in rats and mice. J Pharmacol Exp
Ther 313:395–402
Brennan BP, Roberts JL, Fogarty KV, Reynolds KA, Jonas JM, Hudson
JI (2008) Memantine in the treatment of binge eating disorder: an
open-label, prospective trial. Int J Eat Disord 41:520–526
Buda-Levin A, Wojnicki FH, Corwin RL (2005) Baclofen reduces fat
intake under binge-type conditions. Physiol Behav 86:176–184
Chiamulera C, Epping-Jordan MP, Zocchi A, Marcon C, Cottiny C,
Tacconi S, Corsi M, Orzi F, Conquet F (2001) Reinforcing and
locomotor stimulant effects of cocaine are absent in mGluR5
null mutant mice. Nat Neurosci 4:873–874
Cifani C, Polidori C, Melotto S, Ciccocioppo R, Massi M (2009) A
preclinical model of binge eating elicited by yo-yo dieting and
stressful exposure to food: effect of sibutramine, fluoxetine,
topiramate, and midazolam. Psychopharmacology (Berl)
204:113–125
Colantuoni C, Schwenker J, McCarthy J, Rada P, Ladenheim B,
Cadet JL, Schwartz GJ, Moran TH, Hoebel BG (2001) Excessive
sugar intake alters binding to dopamine and mu-opioid receptors
in the brain. NeuroReport 12:3549–3552
Corwin RL, Buda-Levin A (2004) Behavioral models of binge-type
eating. Physiol Behav 82:123–130
Corwin RL, Wojnicki FH, Fisher JO, Dimitriou SG, Rice HB, Young
MA (1998) Limited access to a dietary fat option affects
ingestive behavior but not body composition in male rats.
Physiol Behav 65:545–553
Devlin MJ, Yanovski SZ, Wilson GT (2000) Obesity: what mental
health professionals need to know. Am J Psychiatry 157:854–866
Devlin MJ, Goldfein JA, Dobrow I (2003) What is this thing called
BED? Current status of binge eating disorder nosology. Int J Eat
Disord 34(Suppl):S2–S18
Erlanson-Albertsson C (2005) How palatable food disrupts appetite
regulation. Basic Clin Pharmacol Toxicol 97:61–73
Fairburn CG, Cooper Z, Doll HA, Norman P, O’Connor M (2000)
The natural course of bulimia nervosa and binge eating disorder
in young women. Arch Gen Psychiatry 57:659–665
Foltin RW, Danysz W, Bisaga A (2008) A novel procedure for assessing
the effects of drugs on satiation in baboons: effects of memantine
and dexfenfluramine. Psychopharmacology (Berl) 199:583–592
Gass JT, Olive MF (2008) Glutamatergic substrates of drug addiction
and alcoholism. Biochem Pharmacol 75:218–265
Hagan MM, Chandler PC, Wauford PK, Rybak RJ, Oswald KD
(2003) The role of palatable food and hunger as trigger factors in
an animal model of stress induced binge eating. Int J Eat Disord
34:183–197
Herman BH, Frankenheim J, Litten RZ, Sheridan PH, Weight FF, Zukin
SR (2003) Glutamate and addiction. Humana Press, Totowa
Hermanussen M, Tresguerres JA (2005) A new anti-obesity drug
treatment: first clinical evidence that, antagonising glutamate-
gated Ca2? ion channels with memantine normalises binge-
eating disorders. Econ Hum Biol 3:329–337
Jackson HC, Needham AM, Hutchins LJ, Mazurkiewicz SE, Heal DJ
(1997) Comparison of the effects of sibutramine and other
monoamine reuptake inhibitors on food intake in the rat. Br J
Pharmacol 121:1758–1762
James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S,
Saris WH, Van Gaal LF (2000) Effect of sibutramine on weight
maintenance after weight loss: a randomised trial. STORM
Study Group. Sibutramine Trial of Obesity Reduction and
Maintenance. Lancet 356:2119–2125
Koros E, Rosenbrock H, Birk G, Weiss C, Sams-Dodd F (2007) The
selective mGlu5 receptor antagonist MTEP, similar to NMDA
receptor antagonists, induces social isolation in rats. Neuropsy-
chopharmacology 32:562–576
Lee JH, Herzog TA, Meade CD, Webb MS, Brandon TH (2007) The use
of GEE for analyzing longitudinal binomial data: a primer using
data from a tobacco intervention. Addict Behav 32:187–193
McShane R, Areosa Sastre A, Minakaran N (2006) Memantine for
dementia. Cochrane Database Syst Rev CD003154
Mitchell JE, Gosnell BA, Roerig JL, de Zwaan M, Wonderlich SA,
Crosby RD, Burgard MA, Wambach BN (2003) Effects of
sibutramine on binge eating, hunger, and fullness in a laboratory
human feeding paradigm. Obes Res 11:599–602
Popik P, Wrobel M, Rygula R, Bisaga A, Bespalov AY (2003) Effects
of memantine, an NMDA receptor antagonist on place prefer-
ence conditioned with drug and non-drug reinforcers in mice.
Behav Pharmacol 14:237–244
Popik P, Wrobel M, Bisaga A (2006) Reinstatement of morphine
conditioned reward is blocked by memantine. Neuropsycho-
pharmacology 31:160–170
Rammes G, Danysz W, Parsons CG (2008) Pharmacodynamics of
memantine: an update. Curr Neuropharmacol 6:55–78
Saper CB, Chou TC, Elmquist JK (2002) The need to feed:
homeostatic and hedonic control of eating. Neuron 36:199–211
Tanofsky-Kraff M, Cohen ML, Yanovski SZ, Cox C, Theim KR, Keil
M, Reynolds JC, Yanovski JA (2006) A prospective study of
psychological predictors of body fat gain among children at high
risk for adult obesity. Pediatrics 117:1203–1209
Vartanian LR, Schwartz MB, Brownell KD (2007) Effects of soft
drink consumption on nutrition and health: a systematic review
and meta-analysis. Am J Public Health 97:667–675
Walsh BT, Devlin MJ (1998) Eating disorders: progress and
problems. Science 280:1387–1390
Weltzin TE, Hsu LK, Pollice C, Kaye WH (1991) Feeding patterns in
bulimia nervosa. Biol Psychiatry 30:1093–1110
Wilfley DE, Crow SJ, Hudson JI, Mitchell JE, Berkowitz RI, Blakesley
V, Walsh BT (2008) Efficacy of sibutramine for the treatment of
binge eating disorder: a randomized multicenter placebo-con-
trolled double-blind study. Am J Psychiatry 165:51–58
Wojnicki FH, Charny G, Corwin RL (2008a) Binge-type behavior in rats
consuming trans-fat-free shortening. Physiol Behav 94:627–629
Wojnicki FH, Johnson DS, Corwin RL (2008b) Access conditions
affect binge-type shortening consumption in rats. Physiol Behav
95:649–657
Wong KJ, Wojnicki FH, Corwin RL (2009) Baclofen, raclopride, and
naltrexone differentially affect intake of fat/sucrose mixtures
under limited access conditions. Pharmacol Biochem Behav
92:528–536
Yanovski SZ (2003) Binge eating disorder and obesity in 2003: could
treating an eating disorder have a positive effect on the obesity
epidemic? Int J Eat Disord 34(Suppl):S117–S120
Zeger SL, Liang KY (1986) Longitudinal data analysis for discrete
and continuous outcomes. Biometrics 42:121–130
Memantine reduces consumption of highly palatable food 485
123
